OrbiMed’s ACELYRIN SLRN Stock Holding History

OrbiMed’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,001,711	Closed	-$9.88M	–	115
2025 Q1	$9.88M	Hold	4,001,711	–	–	0.24%	62
2024 Q4	$12.6M	Hold	4,001,711	–	–	0.26%	67
2024 Q3	$19.7M	Hold	4,001,711	–	–	0.36%	65
2024 Q2	$17.6M	Hold	4,001,711	–	–	0.35%	62
2024 Q1	$27M	Hold	4,001,711	–	–	0.49%	55
2023 Q4	$29.9M	Sell	4,001,711 -1,324,591	-25%	-$11.3M	0.6%	55
2023 Q3	$54.2M	Hold	5,326,302	–	–	1.15%	29
2023 Q2	$111M	Buy	+5,326,302	New	+$109M	2.02%	12

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

OrbiMed's SLRN Position: Q2 2025 in Review

OrbiMed sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 4,001,711 shares — an estimated $9.88M sold.

OrbiMed first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $111M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

OrbiMed reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 4,001,711 ACELYRIN shares in Q2 2025, an estimated $9.88M.
OrbiMed first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
OrbiMed's ACELYRIN position peaked at $111M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.